Clinical trial • Phase III • Oncology

BI 765063 for Non-small cell lung cancer|Melanoma|Head and neck squamous cell carcinoma

Phase III trial of BI 765063 for Non-small cell lung cancer|Melanoma|Head and neck squamous cell carcinoma. 13 participants.

Overview

Trial Therapeutic Area
Oncology
Trial Disease
Non-small cell lung cancer|Melanoma|Head and neck squamous cell carcinoma
Trial Stage
Phase III
Drug Modality
Other|Other|Monoclonal antibody

Key dates

Initial CTIS Submission Date
15-07-2024
First CTIS Authorization Date
29-07-2024

Trial design

Phase III trial across 1 site in Netherlands.

Target Sample Size
13

Recruitment

Planned Sample Size
13
Recruitment Window Months
31

Geography

Total Number Of Sites
1
Total Number Of Participants
13

Netherlands

Earliest CTIS Part Ii Submission Date
25-07-2024
Latest Decision Or Authorization Date
29-07-2024
Processing Time Days
4
Number Of Sites
1
Number Of Participants
13

Sites

Site Name
Stichting Amsterdam UMC
Department Name
Radiology & Nuclear Medicine
Contact Person Name
Willemien van der Houven van Oordt
Contact Person Email
c.menke@vumc.nl

Sponsor

Primary sponsor

Full Name
Boehringer Ingelheim International GmbH
Organisation Type
Pharmaceutical company
Country Of Registered Address
Germany

Investigational products

Investigational Product Name
BI 765063
Modality
Other
Investigational Product Name
BI 770371
Modality
Other
Investigational Product Name
Ezabenlimab
Modality
Monoclonal antibody
Combination Treatment
Yes

Related trials

Other published trials that may interest you.